Understand how emerging immunotherapy combinations and novel approaches are influencing global clinical research in oncology and hematology, with a focus on clinical trial design innovations and mechanistic synergies.

The oncology and hematology clinical research landscape continues to be reshaped by emerging immunotherapy combinations and novel trial approaches. Researchers are exploring immunotherapy combinations to overcome treatment resistance, and ongoing clinical trials are evaluating their effectiveness when paired with other treatments.

It is critical to understand the science and technology behind these novel approaches, and to know how to operationalize them in a clinical trial setting.

Key Discussion Points:

• Understanding advances in immune checkpoint inhibitors (ICIs), T-cell transfer therapy, monoclonal antibodies, antibody drug conjugates (ADC), immune system modulators, and cancer treatment vaccines
• Trials to evaluate immunotherapy effectiveness when paired with targeted therapies, chemotherapy, or radiation in various cancers
• Keys to developing an effective regulatory strategy for novel and immunotherapy studies
• Navigate critical inflection points in your drug development process
• Take advantage of medical, scientific, and operational collaboration